Navigation Links
Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
Date:4/29/2008

PARIS, April 30 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces changes in its Supervisory Board.

Following the annual shareholders' meeting of the Company, that was held on April 25th, 2008, Mr. Edmund Olivier de Vezin's appointment as member of the Supervisory Board, and as vice-chairman of the Board, expired as he has reached the age limit defined in the Company by-laws. The Supervisory Board then appointed Mr. Patrick Langlois, who had just been re-elected during the shareholders'meeting, as vice-chairman of the Board.

ExonHit Therapeutics'shareholders have also elected Mr. Frederic Desdouits, Ph.D. as member of the Supervisory Board.

Mr. Desdouits has been a partner with Bionest Partners, a consultancy firm focused on Life Sciences since 2005. Before joining Bionest, Frederic was head of Pharma Equity Research and a partner at Exane BNP Paribas. He also was head of a research team at GlaxoWellcome, and a Scientific Consultant for Hoechst and Guest Investigator at the Rockefeller University, New York, where he worked on Alzheimer's Disease. Frederic holds a Ph.D. from the College de France in collaboration with Rhone-Poulenc. He holds an MSc in pharmacology and is a graduate of Ecole Polytechnique. He is also a member of the ACIIA.

"I am delighted to join the Supervisory Board of ExonHit and look forward to contributing to the analysis of strategic opportunities for the growth of ExonHit, based on my experience as a scientist, finance person and consultant" said Mr. Desdouits.

The Supervisory Board is chaired by Mr. Laurent Condomine, and Mr. Patrick Langlois is vice-chairman. The other Board members are Ms. Deborah Smeltzer, Mr. Christophe Jean, Mr. Michel Picot and Mr. Frederic Desdouits.

"We are very pleased to have Frederic Desdouits sitting on the Supervisory Board of ExonHit Therapeutics. His professional background, his knowledge of shareholder expectations and of the competitive environment of the Life Science industry will be a strategic asset to ExonHit" said Philippe Rousseau, Chairman of the Management Board of ExonHit. "Also, we are very grateful to Mr. Edmund Olivier de Vezin for his valuable advice, his unwavering support and his active participation in ExonHit's development during the ten years he has spent with the Company's Board. Mr. Olivier de Vezin, who represents the Oxford BioSceince Partners funds, invested in ExonHit since its inception and remains ExonHit's first shareholder. We are very happy that Mr Olivier de Vezin continues to support with confidence the Company development through the funds he manages."

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer' disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

Contacts

ExonHit Therapeutics

Philippe Rousseau, C.E.O.

Tel: +33-1-58-05-47-00

philippe.rousseau@exonhit.com

This press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.


'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
2. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
3. Danong Chen appointed CEO of Theranostics Health
4. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
5. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
6. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
7. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
8. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
9. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... - Global Strategic Business Report" report to their offering. ... This report analyzes ... US$ Million. Annual estimates and forecasts are provided for the period ... and secondary research. The report profiles 25 companies ...
(Date:3/24/2017)... Mass. , March 24, 2017 Agenus ... of immune checkpoint antibodies and cancer vaccines, today announced ... The 7 th  Annual William Blair and Maidstone Life ... Space Alexandria Center in New York, NY ... March 29 at 9:40 am: Robert ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, ... Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will ... Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):